{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:32:22Z","timestamp":1792618342228,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC). We conducted this research to investigate the clinical characteristics and outcomes of OCCC and to provide additional supporting evidence to aid in the clinical diagnosis and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study investigating the clinical characteristics and survival outcomes of 86 patients with OCCC treated at our center between January 2010 and March 2020. Survival analysis was also performed on 179 patients with OCCC obtained from the Surveillance, Epidemiology and End Results (SEER) cancer registry database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median age of participants was 49.21\u2009\u00b1\u20099.91\u2009years old, and 74.42% of them were diagnosed at early stage. The median CA125 level was 601.48\u2009IU\/mL, while 19.77% of the patients had normal CA125 levels. Sixteen patients (18.60%) had co-existing endometriosis and 8 patients (9.3%) developed venous thromboembolism (VTE). There were 5 patients received suboptimal cytoreduction. Sixty-six patients (76.74%) underwent lymphadenectomy, and only 3 (4.55%) patients had positive lymph nodes. Patients diagnosed at an early stage had higher 3-year overall survival (OS) and progression-free survival (PFS) rates than those with advanced stage OCCC. CA19\u20139 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.025) and ascites (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001) were significantly associated with OS, while HE4 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.027) and ascites (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001) were significantly associated with PFS. Analysis of data from the SEER database showed that positive lymph nodes is also an independent prognostic factor for OS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OCCC often presents at an early stage and young age with a mildly elevated CA125. CA19\u20139, HE4, massive ascites, and positive lymph node are independent prognostic factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08061-7","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T10:03:04Z","timestamp":1616666584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study"],"prefix":"10.1186","volume":"21","author":[{"given":"Chenchen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dabao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8992-7897","authenticated-orcid":false,"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"issue":"1","key":"8061_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8061_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9\u201332. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0084.","journal-title":"Cancer Biol Med"},{"issue":"2","key":"8061_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2017.08.004","volume":"147","author":"KE Oliver","year":"2017","unstructured":"Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG oncology\/gynecologic oncology group experience. Gynecol Oncol. 2017;147(2):243\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.004.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8061_CR4","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e5","volume":"27","author":"SI Kim","year":"2016","unstructured":"Kim SI, Lim MC, Lim J, Won YJ, Seo SS, Kang S, et al. Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. J Gynecol Oncol. 2016;27(1):e5. https:\/\/doi.org\/10.3802\/jgo.2016.27.e5.","journal-title":"J Gynecol Oncol"},{"issue":"9 Suppl 3","key":"8061_CR5","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/IGC.0000000000000289","volume":"24","author":"A Okamoto","year":"2014","unstructured":"Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S20\u20135. https:\/\/doi.org\/10.1097\/IGC.0000000000000289.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"8061_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10815-017-0919-1","volume":"34","author":"A Yamamoto","year":"2017","unstructured":"Yamamoto A, Johnstone EB, Bloom MS, Huddleston HG, Fujimoto VY. A higher prevalence of endometriosis among Asian women does not contribute to poorer IVF outcomes. J Assist Reprod Genet. 2017;34(6):765\u201374. https:\/\/doi.org\/10.1007\/s10815-017-0919-1.","journal-title":"J Assist Reprod Genet"},{"issue":"4","key":"8061_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1470-2045(11)70404-1","volume":"13","author":"CL Pearce","year":"2012","unstructured":"Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(11)70404-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"8061_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ygyno.2019.03.243","volume":"153","author":"H Machida","year":"2019","unstructured":"Machida H, Matsuo K, Yamagami W, Ebina Y, Kobayashi Y, Tabata T, et al. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study. Gynecol Oncol. 2019;153(3):589\u201396. https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.243.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"8061_CR9","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3892\/ol.2020.11252","volume":"19","author":"H Liu","year":"2020","unstructured":"Liu H, Xu Y, Ji J, Dong R, Qiu H, Dai X. Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: a population-based analysis. Oncol Lett. 2020;19(3):1947\u201357. https:\/\/doi.org\/10.3892\/ol.2020.11252.","journal-title":"Oncol Lett"},{"issue":"3","key":"8061_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237\u201349. https:\/\/doi.org\/10.1007\/s00428-012-1203-5.","journal-title":"Virchows Arch"},{"issue":"1","key":"8061_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.fertnstert.2014.03.041","volume":"102","author":"MS Rice","year":"2014","unstructured":"Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' health studies. Fertil Steril. 2014;102(1):192\u20138 e3. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.03.041.","journal-title":"Fertil Steril"},{"issue":"6","key":"8061_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/ijgc-2019-000384","volume":"29","author":"T Enomoto","year":"2019","unstructured":"Enomoto T, Aoki D, Hattori K, Jinushi M, Sugiyama T. The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer. 2019;29(6):1043\u20139. https:\/\/doi.org\/10.1136\/ijgc-2019-000384.","journal-title":"Int J Gynecol Cancer"},{"issue":"21","key":"8061_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010881","volume":"97","author":"H Tang","year":"2018","unstructured":"Tang H, Liu Y, Wang X, Guan L, Chen W, Jiang H, et al. Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort. Medicine (Baltimore). 2018;97(21):e10881. https:\/\/doi.org\/10.1097\/MD.0000000000010881.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"8061_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4143\/crt.2019.292","volume":"52","author":"HY Lee","year":"2020","unstructured":"Lee HY, Hong JH, Byun JH, Kim HJ, Baek SK, Kim JY, et al. Clinical characteristics of clear cell ovarian Cancer: a retrospective multicenter experience of 308 patients in South Korea. Cancer Res Treat. 2020;52(1):277\u201383. https:\/\/doi.org\/10.4143\/crt.2019.292.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"8061_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10147-020-01625-w","volume":"25","author":"K Takahashi","year":"2020","unstructured":"Takahashi K, Takenaka M, Kawabata A, Yanaihara N, Okamoto A. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma. Int J Clin Oncol. 2020;25(3):425\u201331. https:\/\/doi.org\/10.1007\/s10147-020-01625-w.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"8061_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/path.4657","volume":"238","author":"CM King","year":"2016","unstructured":"King CM, Barbara C, Prentice A, Brenton JD, Charnock-Jones DS. Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma. J Pathol. 2016;238(2):185\u201396. https:\/\/doi.org\/10.1002\/path.4657.","journal-title":"J Pathol"},{"issue":"6","key":"8061_CR17","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3892\/mco.2017.1468","volume":"7","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Takano M, Miyamoto M, Soyama H, Matsuura H, Aoyama T, et al. Role of endometriosis as a prognostic factor for post-progression survival in ovarian clear cell carcinoma. Mol Clin Oncol. 2017;7(6):1027\u201331. https:\/\/doi.org\/10.3892\/mco.2017.1468.","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"8061_CR18","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.3802\/jgo.2018.29.e18","volume":"29","author":"ES Paik","year":"2018","unstructured":"Paik ES, Kim T-J, Choi CH, Kim B-G, Bae D-S, Lee J-W. Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. J Gynecol Oncol. 2018;29(2):e18.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"8061_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5468\/ogs.2019.62.1.27","volume":"62","author":"JH Son","year":"2019","unstructured":"Son JH, Yoon S, Kim S, Kong TW, Paek J, Chang SJ, et al. Clinicopathologic characteristics of ovarian clear cell carcinoma in the background of endometrioma: a surveillance strategy for an early detection of malignant transformation in patients with asymptomatic endometrioma. Obstet Gynecol Sci. 2019;62(1):27\u201334. https:\/\/doi.org\/10.5468\/ogs.2019.62.1.27.","journal-title":"Obstet Gynecol Sci"},{"issue":"3","key":"8061_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121818","volume":"10","author":"S Ye","year":"2015","unstructured":"Ye S, Yang J, Cao D, Bai H, Huang H, Wu M, et al. Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study. PLoS One. 2015;10(3):e0121818. https:\/\/doi.org\/10.1371\/journal.pone.0121818.","journal-title":"PLoS One"},{"issue":"6","key":"8061_CR21","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.fertnstert.2014.08.008","volume":"102","author":"Y Shuang","year":"2014","unstructured":"Shuang Y, Yang J, Yan Y, et al. Comparative study of ovarian clear cell carcinoma with and without endometriosis in People's Republic of China. Fertil Steril. 2014;102(6):1656\u201362.","journal-title":"Fertil Steril"},{"issue":"7","key":"8061_CR22","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.7150\/jca.24057","volume":"9","author":"BS Kwon","year":"2018","unstructured":"Kwon BS, Jeong DH, Byun JM, Lee TH, Choi KU, Song YJ, et al. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. J Cancer. 2018;9(7):1127\u201334. https:\/\/doi.org\/10.7150\/jca.24057.","journal-title":"J Cancer"},{"issue":"6","key":"8061_CR23","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e85","volume":"30","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Yoshikawa N, Shirakawa A, Niimi K, Suzuki S, Kajiyama H, et al. Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. J Gynecol Oncol. 2019;30(6):e85. https:\/\/doi.org\/10.3802\/jgo.2019.30.e85.","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"8061_CR24","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e31","volume":"27","author":"S Mabuchi","year":"2016","unstructured":"Mabuchi S, Sugiyama T, Kimura T. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol. 2016;27(3):e31. https:\/\/doi.org\/10.3802\/jgo.2016.27.e31.","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"8061_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cjp2.53","volume":"2","author":"M K\u00f6bel","year":"2016","unstructured":"K\u00f6bel M, Piskorz AM, Lee S, Lui S, Brenton JD. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2(4):247\u201358. https:\/\/doi.org\/10.1002\/cjp2.53.","journal-title":"J Pathol Clin Res"},{"issue":"2","key":"8061_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/COC.0000000000000641","volume":"43","author":"EI Marks","year":"2020","unstructured":"Marks EI, Brown VS, Dizon DS. Genomic and molecular abnormalities in gynecologic clear cell carcinoma. Am J Clin Oncol. 2020;43(2):139\u201345. https:\/\/doi.org\/10.1097\/COC.0000000000000641.","journal-title":"Am J Clin Oncol"},{"key":"8061_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.thromres.2016.12.002","volume":"150","author":"N Swier","year":"2017","unstructured":"Swier N, Versteeg HH. Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression. Thromb Res. 2017;150:8\u201318. https:\/\/doi.org\/10.1016\/j.thromres.2016.12.002.","journal-title":"Thromb Res"},{"issue":"5","key":"8061_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ejso.2020.01.026","volume":"46","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Zhu C, Shen Z, Zhang T, Li M, Zhu J, et al. Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period. Eur J Surg Oncol. 2020;46(5):855\u201361. https:\/\/doi.org\/10.1016\/j.ejso.2020.01.026.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"8061_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1756-9966-31-53","volume":"31","author":"M Takano","year":"2012","unstructured":"Takano M, Tsuda H, Sugiyama T. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? J Exp Clin Cancer Res. 2012;31(1):53. https:\/\/doi.org\/10.1186\/1756-9966-31-53.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"8061_CR30","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3892\/ol.2015.3367","volume":"10","author":"H Kobayashi","year":"2015","unstructured":"Kobayashi H, Sugimoto H, Onishi S, Nakano K. Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma. Oncol Lett. 2015;10(2):612\u20138. https:\/\/doi.org\/10.3892\/ol.2015.3367.","journal-title":"Oncol Lett"},{"issue":"4","key":"8061_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1349-7006.2008.00747.x","volume":"99","author":"H Itamochi","year":"2008","unstructured":"Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008;99(4):653\u20138. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00747.x.","journal-title":"Cancer Sci"},{"issue":"2","key":"8061_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbcan.2018.07.005","volume":"1870","author":"JJ Caumanns","year":"2018","unstructured":"Caumanns JJ, Wisman GBA, Berns K, van der Zee AGJ, de Jong S. ARID1A mutant ovarian clear cell carcinoma: a clear target for synthetic lethal strategies. Biochim Biophys Acta Rev Cancer. 2018;1870(2):176\u201384. https:\/\/doi.org\/10.1016\/j.bbcan.2018.07.005.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"8061_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ygyno.2018.04.572","volume":"150","author":"PA Konstantinopoulos","year":"2018","unstructured":"Konstantinopoulos PA, Brady WE, Farley J, Armstrong A, Uyar DS, Gershenson DM. Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). Gynecol Oncol. 2018;150(1):9\u201313. https:\/\/doi.org\/10.1016\/j.ygyno.2018.04.572.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8061_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10147-018-1319-y","volume":"24","author":"S Komiyama","year":"2019","unstructured":"Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A, et al. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Int J Clin Oncol. 2019;24(1):103\u201314. https:\/\/doi.org\/10.1007\/s10147-018-1319-y.","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"8061_CR35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353. https:\/\/doi.org\/10.1056\/NEJMoa0908806.","journal-title":"N Engl J Med"},{"issue":"9990","key":"8061_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(14)62223-6.","journal-title":"Lancet."},{"issue":"6","key":"8061_CR37","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1097\/IGC.0000000000001293","volume":"28","author":"J Zhu","year":"2018","unstructured":"Zhu J, Jiang L, Wen H, Bi R, Wu X, Ju X. Prognostic value of serum CA19-9 and perioperative CA-125 levels in ovarian clear cell carcinoma. Int J Gynecol Cancer. 2018;28(6):1108\u201316. https:\/\/doi.org\/10.1097\/IGC.0000000000001293.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"8061_CR38","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.3892\/mmr.2015.4062","volume":"12","author":"B McKinnon","year":"2015","unstructured":"McKinnon B, Mueller MD, Nirgianakis K, Bersinger NA. Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125. Mol Med Rep. 2015;12(4):5179\u201384. https:\/\/doi.org\/10.3892\/mmr.2015.4062.","journal-title":"Mol Med Rep"},{"issue":"2","key":"8061_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5114\/pm.2016.61190","volume":"15","author":"M Szubert","year":"2016","unstructured":"Szubert M, Suzin J, Obirek K, Sochacka A, Loszakiewicz M. Clear cell ovarian cancer and endometriosis: is there a relationship? Prz Menopauzalny. 2016;15(2):85\u20139. https:\/\/doi.org\/10.5114\/pm.2016.61190.","journal-title":"Prz Menopauzalny"},{"issue":"1","key":"8061_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/IGC.0000000000000559","volume":"26","author":"JJ Mueller","year":"2016","unstructured":"Mueller JJ, Holzapfel M, Han CH, Santos K, Gunderson C, Moore K, et al. Staging lymphadenectomy in patients with clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2016;26(1):120\u20134. https:\/\/doi.org\/10.1097\/IGC.0000000000000559.","journal-title":"Int J Gynecol Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08061-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-08061-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08061-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T10:05:50Z","timestamp":1616666750000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08061-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8061"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08061-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-81462\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was ethically reviewed and approved by the ethics committees of The First Affiliated Hospital of USTC. Since this study does not involve the collection of human tissues, blood and other samples, only the original medical records would be collected for retrospective analysis, we obtained verbal informed consent from all participants, and the ethics committee approved this procedure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"322"}}